|Bid||1.3800 x 3000|
|Ask||1.4900 x 2200|
|Day's Range||1.4100 - 1.5200|
|52 Week Range||0.4600 - 3.8900|
|Beta (5Y Monthly)||2.00|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2022 - Nov 04, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.17|
Subscribe to Yahoo Finance Plus to view Fair Value for INFI
Every investor in Infinity Pharmaceuticals, Inc. ( NASDAQ:INFI ) should be aware of the most powerful shareholder...
Infinity (INFI) delivered earnings and revenue surprises of 7.14% and 1.63%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
CAMBRIDGE, Mass., August 09, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its second quarter 2022 financial results, unveiled new positive data from the Phase 2 MARIO-275 clinical trial, and provided a business update.